Search

Your search keyword '"Nahi, Hareth"' showing total 896 results
Start Over Author "Nahi, Hareth"
896 results on '"Nahi, Hareth"'

2. Teclistamab in Relapsed or Refractory Multiple Myeloma

Author

Moreau, Philippe, Garfall, Alfred L, van de Donk, Niels WCJ, Nahi, Hareth, San-Miguel, Jesús F, Oriol, Albert, Nooka, Ajay K, Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Delforge, Michel, Pei, Lixia, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Lin, Shun XW, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa, Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D, Kobos, Rachel, Krishnan, Amrita, and Usmani, Saad Z

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Hematology, Immunotherapy, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Cancer, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, B-Cell Maturation Antigen, CD3 Complex, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundTeclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.MethodsIn this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better).ResultsAmong 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).ConclusionsTeclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).

Published
2022

5. Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.

Author

Luo, Man, Usmani, Saad, Mateos, Maria-Victoria, Nahi, Hareth, Chari, Ajai, San-Miguel, Jesus, Touzeau, Cyrille, Suzuki, Kenshi, Kaiser, Martin, Carson, Robin, Heuck, Christoph, Qi, Ming, Zhou, Honghui, Sun, Yu-Nien, and Parasrampuria, Dolly

Subjects
biologics, daratumumab, multiple myeloma, pharmacokinetics, subcutaneous, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Body Mass Index, Female, Humans, Injections, Intravenous, Injections, Subcutaneous, Liver Function Tests, Male, Metabolic Clearance Rate, Middle Aged, Multiple Myeloma
Abstract

We report the population pharmacokinetic (PK) and exposure-response analyses of a novel subcutaneous formulation of daratumumab (DARA) using data from 3 DARA subcutaneous monotherapy studies (PAVO Part 2, MMY1008, COLUMBA) and 1 combination therapy study (PLEIADES). Results were based on 5159 PK samples from 742 patients (DARA 1800 mg subcutaneously, n = 487 [monotherapy, n = 288; combination therapy, n = 199]; DARA 16 mg/kg intravenously, n = 255 [all monotherapy, in COLUMBA]; age, 33-92 years; weight, 28.6-147.6 kg). Subcutaneous and intravenous DARA monotherapies were administered once every week for cycles 1-2, once every 2 weeks for cycles 3-6, and once every 4 weeks thereafter (1 cycle is 28 days). The subcutaneous DARA combination therapy was administered with the adaptation of corresponding standard-of-care regimens. PK samples were collected between cycle 1 and cycle 12. Among monotherapy studies, throughout the treatment period, subcutaneous DARA provided similar/slightly higher trough concentrations (Ctrough ) versus intravenous DARA, with lower maximum concentrations and smaller peak-to-trough fluctuations. The PK profile was consistent between subcutaneous DARA monotherapy and combination therapies. The exposure-response relationship between daratumumab PK and efficacy or safety end points was similar for subcutaneous and intravenous DARA. Although the ≤65-kg subgroup reported a higher incidence of neutropenia, no relationship was found between the incidence of neutropenia and exposure, which was attributed, in part, to the preexisting imbalance in neutropenia between subcutaneous DARA (45.5%) and intravenous DARA (19%) in patients ≤50 kg. A flat relationship was observed between body weight and any grade and at least grade 3 infections. The results support the DARA 1800-mg subcutaneous flat dose as an alternative to the approved intravenous DARA 16 mg/kg.

Published
2021

6. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.

Author

Perrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad, Kumar, Shaji, Bahlis, Nizar, Hulin, Cyrille, Orlowski, Robert, Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, He, Jianming, Ho, Kai, Van Rampelbergh, Rian, Uhlar, Clarissa, Wang, Jianping, Kobos, Rachel, Gries, Katharine, Fastenau, John, and Weisel, Katja

Subjects
Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Lenalidomide, Male, Middle Aged, Multiple Myeloma, Pain Measurement, Patient Reported Outcome Measures, Quality of Life, Time Factors, Treatment Outcome
Abstract

PURPOSE: To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs) in the phase III MAIA study. PATIENTS AND METHODS: PROs were assessed on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item and the EuroQol 5-dimensional descriptive system at baseline and every 3 months during treatment. By mixed-effects model, changes from baseline are presented as least squares means with 95% CIs. RESULTS: A total of 737 transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma were randomly assigned to D-Rd (n = 368) or Rd (n = 369). Compliance with PRO assessments was high at baseline (> 90%) through month 12 (> 78%) for both groups. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item global health status scores improved from baseline in both groups and were consistently greater with D-Rd at all time points. A global health status benefit was achieved with D-Rd, regardless of age (< 75 and ≥ 75 years), baseline Eastern Cooperative Oncology Group (ECOG) performance status score, or depth of response. D-Rd treatment resulted in significantly greater reduction in pain scores as early as cycle 3 (P = .0007 v Rd); the magnitude of change was sustained through cycle 12. Reductions in pain with D-Rd were clinically meaningful in patients regardless of age, ECOG status, or depth of response. Similarly, PRO improvements were observed with D-Rd and Rd on the EuroQol 5-dimensional descriptive system visual analog scale score. CONCLUSION: D-Rd compared with Rd was associated with faster and sustained clinically meaningful improvements in PROs, including pain, in transplant-ineligible patients with newly diagnosed multiple myeloma regardless of age, baseline ECOG status, or depth of treatment response.

Published
2021

7. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

Author

Facon, Thierry, Cook, Gordon, Usmani, Saad Z., Hulin, Cyrille, Kumar, Shaji, Plesner, Torben, Touzeau, Cyrille, Bahlis, Nizar J., Basu, Supratik, Nahi, Hareth, Goldschmidt, Hartmut, Quach, Hang, Mohty, Mohamad, Venner, Christopher P., Weisel, Katja, Raje, Noopur, Hebraud, Benjamin, Belhadj-Merzoug, Karim, Benboubker, Lotfi, Decaux, Olivier, Manier, Salomon, Caillot, Denis, Ukropec, Jon, Pei, Huiling, Van Rampelbergh, Rian, Uhlar, Clarissa M., Kobos, Rachel, and Zweegman, Sonja

Published
2022
Full Text
View/download PDF

8. Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma

Author

Nahi, Hareth, Chrobok, Michael, Meinke, Stephan, Gran, Charlotte, Marquardt, Nicole, Afram, Gabriel, Sutlu, Tolga, Gilljam, Mari, Stellan, Birgitta, Wagner, Arnika K., Blomberg, Pontus, Holmqvist, Per-Henrik, Walther-Jallow, Lilian, Mellström, Karin, Liwing, Johan, Gustafsson, Charlotte, Månsson, Robert, Klimkowska, Monika, Gahrton, Gösta, Lund, Johan, Ljungman, Per, Ljunggren, Hans-Gustaf, and Alici, Evren

Published
2022
Full Text
View/download PDF

10. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Author

Facon, Thierry, Kumar, Shaji K, Plesner, Torben, Orlowski, Robert Z, Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, O'Dwyer, Michael, Perrot, Aurore, Venner, Christopher P, Weisel, Katja, Mace, Joseph R, Raje, Noopur, Tiab, Mourad, Macro, Margaret, Frenzel, Laurent, Leleu, Xavier, Ahmadi, Tahamtan, Wang, Jianping, Van Rampelbergh, Rian, Uhlar, Clarissa M, Tromp, Brenda, Delioukina, Maria, Vermeulen, Jessica, and Usmani, Saad Z

Published
2021
Full Text
View/download PDF

11. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Author

Usmani, Saad Z, Garfall, Alfred L, van de Donk, Niels W C J, Nahi, Hareth, San-Miguel, Jesus F, Oriol, Albert, Rosinol, Laura, Chari, Ajai, Bhutani, Manisha, Karlin, Lionel, Benboubker, Lotfi, Pei, Lixia, Verona, Raluca, Girgis, Suzette, Stephenson, Tara, Elsayed, Yusri, Infante, Jeffrey, Goldberg, Jenna D, Banerjee, Arnob, Mateos, María-Victoria, and Krishnan, Amrita

Published
2021
Full Text
View/download PDF

12. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Author

Moreau, Philippe, Kumar, Shaji K, San Miguel, Jesús, Davies, Faith, Zamagni, Elena, Bahlis, Nizar, Ludwig, Heinz, Mikhael, Joseph, Terpos, Evangelos, Schjesvold, Fredrik, Martin, Thomas, Yong, Kwee, Durie, Brian G M, Facon, Thierry, Jurczyszyn, Artur, Sidana, Surbhi, Raje, Noopur, van de Donk, Niels, Lonial, Sagar, Cavo, Michele, Kristinsson, Sigurdur Y, Lentzsch, Suzanne, Hajek, Roman, Anderson, Kenneth C, João, Cristina, Einsele, Hermann, Sonneveld, Pieter, Engelhardt, Monika, Fonseca, Rafael, Vangsted, Annette, Weisel, Katja, Baz, Rachid, Hungria, Vania, Berdeja, Jesus G, Leal da Costa, Fernando, Maiolino, Angelo, Waage, Anders, Vesole, David H, Ocio, Enrique M, Quach, Hang, Driessen, Christoph, Bladé, Joan, Leleu, Xavier, Riva, Eloisa, Bergsagel, Peter Leif, Hou, Jian, Chng, Wee Joo, Mellqvist, Ulf-Henrik, Dytfeld, Dominik, Harousseau, Jean-Luc, Goldschmidt, Hartmut, Laubach, Jacob, Munshi, Nikhil C, Gay, Francesca, Beksac, Meral, Costa, Luciano J, Kaiser, Martin, Hari, Parameswaran, Boccadoro, Mario, Usmani, Saad Z, Zweegman, Sonja, Holstein, Sarah, Sezer, Orhan, Harrison, Simon, Nahi, Hareth, Cook, Gordon, Mateos, Maria-Victoria, Rajkumar, S Vincent, Dimopoulos, Meletios A, and Richardson, Paul G

Published
2021
Full Text
View/download PDF

13. Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden

Author

Uttervall, Katarina, Tätting, Love, Lemonakis, Konstantinos, Majd, Mousa, Crafoord, Jacob, Olsson, Mikael, Mellqvist, Ulf-Henrik, Hansson, Markus, Nahi, Hareth, Uttervall, Katarina, Tätting, Love, Lemonakis, Konstantinos, Majd, Mousa, Crafoord, Jacob, Olsson, Mikael, Mellqvist, Ulf-Henrik, Hansson, Markus, and Nahi, Hareth

Abstract

Background: Multiple myeloma (MM), an incurable disease characterized by frequent relapses and a need for multiple treatments, often progresses to a relapse/refractory status resistant to all available drugs and drug classes. Bispecific antibodies, specifically BCMA T-cell engagers, have emerged as effective treatments for MM, demonstrating impressive efficacy. However, these treatments can adversely affect the immune system, increasing vulnerability to infections. Methods/Results: This study evaluated the efficacy and safety of BCMA T-cell engagers in 58 Swedish patients with poor MM prognosis. The patients exhibited a 69% overall response rate, with 69% survival and 60% progression-free survival at 15 months. Conclusions: Despite the risk of infectious complications, the prognosis of MM patients can be significantly improved with vigilant monitoring and proactive management of infections. This real-world data highlight the potential of BCMA T-cell engagers in treating MM, emphasizing the need for careful patient monitoring to mitigate infection risks., Funding Agencies|Cancerfonden; [4-2528/2019]

Published
2024
Full Text
View/download PDF

14. Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

Author

Partanen, Anu, Waage, Anders, Peceliunas, Valdas, Schjesvold, Fredrik, Anttila, Pekka, Saeily, Marjaana, Uttervall, Katarina, Putkonen, Mervi, Carlson, Kristina, Haukas, Einar, Sankelo, Marja, Szatkowski, Damian, Hansson, Markus, Marttila, Anu, Svensson, Ronald, Axelsson, Per, Lauri, Birgitta, Mikkola, Maija, Karlsson, Conny, Abelsson, Johanna, Ahlstrand, Erik, Sikioe, Anu, Klimkowska, Monika, Matuzeviciene, Reda, Fenstad, Mona Hoysaeter, Ilveskero, Sorella, Pelliniemi, Tarja-Terttu, Nahi, Hareth, Silvennoinen, Raija, Partanen, Anu, Waage, Anders, Peceliunas, Valdas, Schjesvold, Fredrik, Anttila, Pekka, Saeily, Marjaana, Uttervall, Katarina, Putkonen, Mervi, Carlson, Kristina, Haukas, Einar, Sankelo, Marja, Szatkowski, Damian, Hansson, Markus, Marttila, Anu, Svensson, Ronald, Axelsson, Per, Lauri, Birgitta, Mikkola, Maija, Karlsson, Conny, Abelsson, Johanna, Ahlstrand, Erik, Sikioe, Anu, Klimkowska, Monika, Matuzeviciene, Reda, Fenstad, Mona Hoysaeter, Ilveskero, Sorella, Pelliniemi, Tarja-Terttu, Nahi, Hareth, and Silvennoinen, Raija

Abstract

Scarce data exist on double maintenance in transplant-eligible high-risk (HR) newly diagnosed multiple myeloma (NDMM) patients. This prospective phase 2 study enrolled 120 transplant-eligible NDMM patients. The treatment consisted of four cycles of ixazomib-lenalidomide-dexamethasone (IRD) induction plus autologous stem cell transplantation followed by IRD consolidation and cytogenetic risk-based maintenance therapy with lenalidomide + ixazomib (IR) for HR patients and lenalidomide (R) alone for NHR patients. The main endpoint of the study was undetectable minimal residual disease (MRD) with sensitivity of <10-5 by flow cytometry at any time, and other endpoints were progression-free survival (PFS) and overall survival (OS). We present the preplanned analysis after the last patient has been two years on maintenance. At any time during protocol treatment, 28% (34/120) had MRD < 10-5 at least once. At two years on maintenance, 66% of the patients in the HR group and 76% in the NHR group were progression-free (p = 0.395) and 36% (43/120) were CR or better, of which 42% (18/43) had undetectable flow MRD <10-5. Altogether 95% of the patients with sustained MRD <10-5, 82% of the patients who turned MRD-positive, and 61% of those with positive MRD had no disease progression at two years on maintenance (p < 0.001). To conclude, prolonged maintenance with all-oral ixazomib plus lenalidomide might improve PFS in HR patients., Funding Agencies|BMS

Published
2024
Full Text
View/download PDF

17. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

Author

Mateos, Maria-Victoria, Nahi, Hareth, Legiec, Wojciech, Grosicki, Sebastian, Vorobyev, Vladimir, Spicka, Ivan, Hungria, Vania, Korenkova, Sibirina, Bahlis, Nizar, Flogegard, Max, Bladé, Joan, Moreau, Philippe, Kaiser, Martin, Iida, Shinsuke, Laubach, Jacob, Magen, Hila, Cavo, Michele, Hulin, Cyrille, White, Darrell, De Stefano, Valerio, Clemens, Pamela L, Masterson, Tara, Lantz, Kristen, O'Rourke, Lisa, Heuck, Christoph, Qin, Xiang, Parasrampuria, Dolly A, Yuan, Zhilong, Xu, Steven, Qi, Ming, and Usmani, Saad Z

Published
2020
Full Text
View/download PDF

18. Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

Author

Partanen, Anu, primary, Waage, Anders, additional, Peceliunas, Valdas, additional, Schjesvold, Fredrik, additional, Anttila, Pekka, additional, Säily, Marjaana, additional, Uttervall, Katarina, additional, Putkonen, Mervi, additional, Carlson, Kristina, additional, Haukas, Einar, additional, Sankelo, Marja, additional, Szatkowski, Damian, additional, Hansson, Markus, additional, Marttila, Anu, additional, Svensson, Ronald, additional, Axelsson, Per, additional, Lauri, Birgitta, additional, Mikkola, Maija, additional, Karlsson, Conny, additional, Abelsson, Johanna, additional, Ahlstrand, Erik, additional, Sikiö, Anu, additional, Klimkowska, Monika, additional, Matuzeviciene, Reda, additional, Fenstad, Mona Hoysaeter, additional, Ilveskero, Sorella, additional, Pelliniemi, Tarja-Terttu, additional, Nahi, Hareth, additional, and Silvennoinen, Raija, additional

Published
2024
Full Text
View/download PDF

19. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

Author

Usmani, Saad Z., Mateos, Maria-Victoria, Hungria, Vania, Iida, Shinsuke, Bahlis, Nizar J., Nahi, Hareth, Magen, Hila, Cavo, Michele, Hulin, Cyrille, White, Darrell, De Stefano, Valerio, Fastenau, John, Slavcev, Mary, Heuck, Christoph, Qin, Xiang, Pei, Huiling, Masterson, Tara, Lantz, Kristen, and Gries, Katharine S.

Published
2021
Full Text
View/download PDF

20. Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Author

Morris, Curly, Chabannon, Christian, Masszi, Tamas, Russell, Nigel, Nahi, Hareth, Kobbe, Guido, Krejci, Marta, Auner, Holger W., Pohlreich, David, Hayden, Patrick, Basak, Grzegorz W., Lenhoff, Stig, Schaap, Nicolaas, van Biezen, Anja, Knol, Cora, Iacobelli, Simona, Liu, Qianying, Celanovic, Marina, Garderet, Laurent, and Kröger, Nicolaus

Published
2020
Full Text
View/download PDF

22. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Author

Abildgaard, Niels, Adler, Howard, Altuntas, Fevzi, Akay, Olga Meltem, Amin, Bipinkumar, Anagnostopoulos, Achilleas, Anderson, Larry, Anttila, Pekka, Araujo, Carla, Arce-Lara, Carlos, Aydin, Yildiz, Basu, Supratik, Battini, Ramakrishna, Beeker, Thaddeus, Benboubker, Lotfi, Ben-Yehuda, Dina, Bladé, Joan, Blau, Igor Wolfgang, Boccia, Ralph, Burke, Lillian, Byeff, Peter, Cascavilla, Nicola, Cavo, Michele, Chantry, Andrew, Charles, Yen, Chaudhry, Arvind, Corso, Alessandro, Coyne, Mark, De Arriba, Felipe, Delimpasi, Sosana, Desjardins, Pierre, Dhakal, Binod, Di Bartolomeo, Paolo, Di Raimondo, Francesco, Dürig, Jan, Engelhardt, Monika, Escoffre-Barbe, Martine, Esteves, Graca, Flogegard, Max, Gabrail, Nashat, Gamberi, Barbara, Garrison, Mitchell, Gay, Julie, Gisslinger, Heinz, Goldschmidt, Hartmut, Goncalves, Cristina, Gressot, Laurent, Grosicki, Sebastian, Hanna, Wahid, Hayden, Patrick, Henriques Bernardo, Maria Manuela, Hermann, Robert, Holden, Viran, Honkalehto, Kirsti, Huben, Marianne, Huffman, John, Hunter, Hannah, Hus, Marek, Jagasia, Madan, Jagganath, Sundar, Janakiram, Murali, Jaiyesimi, Ishmael, Jenner, Matthew, João, Cristina, Johnson, Peter, Jurcyszyn, Artur, Kalayoğlu Beşişik, Sevgi, Kambhampati, Suman, Kanate, Abraham, Karadoğan, Ihsan, Khojasteh, Ali, Kirkel, Dean, Komarnicki, Mieczyslaw, Krauth, Maria-Theresa, Kuriakose, Phillip, Larocca, Alessandra, Lauri, Birgitta, Leleu, Xavier, Lucio, Paulo, Luppi, Mario, Mangiacavalli, Silvia, Mariette, Clara, Matsue, Kosei, Mellqvist, Ulf-Henri, Mendeleeva, Larisa, Meshad, Michael, Miller, Carole, Mohrbacher, Ann, Moreau, Philippe, Morelli, Anna Maria, Müldür, Ercan, Naassan, Anthony, Nahi, Hareth, Nair, Rajesh, O'Dwyer, Mike, Öngören Aydin, Seniz, Openshaw, Thomas, O'Rourke, Timothy, Osswald, Michael, Overton, Lindsay, Pati, Asmin, Pavic, Michel, Pegourie, Brigitte, Pehlivan, Mustafa, Pierola, Ana Alfonso, Plesner, Torben, Pluta, Andrzej, Rabin, Neil, Ramasamy, Karthik, Rambaldi, Alessandro, Rodriguez, Paula, Röllig, Christoph, Rosenblatt, Jacalyn, Rosenbluth, Jonathan, Salomo, Morten, Samoylova, Olga, Sastre Moral, Jose, Sati, Hamdi, Selleri, Carmine, Shafeek, Salim, Shinagawa, Atsushi, Sleckman, Bethany, Smith, Clay, Sonmez, Mehmet, Stone, Chester, Streetly, Matthew, Suzuki, Kenshi, Taetle, Raymond, Tafuri, Agostino, Takezako, Naoki, Teke, Hava Üsküdar, Vapaatalo, Mirja, Vassilopoulos, George, Verma, Amit, Vidito, Sarah, Viterbo, Luisa, Vural, Filiz, Wang, Xiang Sean, Yağci, Munci, Yee, Andrew, Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thomas, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, and Dimopoulos, Meletios

Published
2019
Full Text
View/download PDF

24. OA-10 Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple myeloma

Author

Gundesen, Michael, primary, Schjesvold, Fredrik, additional, Vangsted, Annette Juul, additional, Helleberg, Carsten, additional, Haukås, Einar, additional, Silkjær, Trine, additional, Teodorescu, Elena Manuela, additional, Jensen, Bo Amdi, additional, Slørdahl, Tobias, additional, Asmussen, Jon Thor, additional, Nahi, Hareth, additional, Abildgaard, Niels, additional, and Lund, Thomas, additional

Published
2023
Full Text
View/download PDF

25. MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study

Author

Usmani, Saad Z, primary, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Nahi, Hareth, additional, San-Miguel, Jesús, additional, Trancucci, Danielle, additional, Qi, Keqin, additional, Stephenson, Tara, additional, Puchalt, Alfredo Perales, additional, Chastain, Katherine, additional, and Chari, Ajai, additional

Published
2023
Full Text
View/download PDF

26. POSTER: MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study

Author

Usmani, Saad Z, primary, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Nahi, Hareth, additional, San-Miguel, Jesús, additional, Trancucci, Danielle, additional, Qi, Keqin, additional, Stephenson, Tara, additional, Puchalt, Alfredo Perales, additional, Chastain, Katherine, additional, and Chari, Ajai, additional

Published
2023
Full Text
View/download PDF

28. Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment

Author

Reinoso-Segura, Marta, Caballero-Velázquez, Teresa, Herrera, Pilar, Patriarca, Francesca, Fanin, Renato, Bruno, Benedetto, Einsele, Hermann, Nahi, Hareth, Granell, Miquel, López-Corral, Lucía, Reguera, Juan L., García-Cadenas, Irene, Gahrton, Gösta, and Pérez-Simón, José A.

Published
2022
Full Text
View/download PDF

29. P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY

Author

Bhutani, Manisha, primary, Garfall, Alfred, additional, Uttervall, Katarina, additional, Usmani, Saad Z, additional, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Nahi, Hareth, additional, San Miguel, Jesús, additional, Trancucci, Danielle, additional, Qi, Keqin, additional, Stephenson, Tara, additional, Perales-Puchalt, Alfredo, additional, Chastain, Katherine, additional, and Chari, Ajai, additional

Published
2023
Full Text
View/download PDF

30. P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS

Author

Silvennoinen, Raija, primary, Partanen, Anu, additional, Waage, Anders, additional, Pečeliūnas, Valdas, additional, Schjesvold, Fredrik, additional, Anttila, Pekka, additional, Uttervall, Katarina, additional, Säily, Marjaana, additional, Putkonen, Mervi, additional, Carlson, Kristina, additional, Haukas, Einar, additional, Sankelo, Marja, additional, Szatkowski, Damian, additional, Hansson, Markus, additional, Marttila, Anu, additional, Axelsson, Per, additional, Svensson, Ronald, additional, Lauri, Birgitta, additional, Mikkola, Maija, additional, Karlsson, Conny, additional, Abelsson, Johanna, additional, Ahlstrand, Erik, additional, Sikiö, Anu, additional, Klimkowska, Monika, additional, Matuzeviciene, Reda, additional, Hoyseter Fenstad, Mona, additional, Ilveskero, Sorella, additional, and Nahi, Hareth, additional

Published
2023
Full Text
View/download PDF

31. P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.

Author

Gundesen, Michael, primary, Schjesvold, Fredrik, additional, Vangsted, Annette, additional, Helleberg, Carsten, additional, Haukås, Einar, additional, Silkjær, Trine, additional, Todorescu, Elena, additional, Amdi Jensen, Bo, additional, Slørdahl, Tobias S., additional, Thor Asmussen, Jon, additional, Nahi, Hareth, additional, Waage, Anders, additional, Abildgaard, Niels, additional, and Lund, Thomas, additional

Published
2023
Full Text
View/download PDF

32. Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

Author

Went, Molly, Sud, Amit, Försti, Asta, Halvarsson, Britt-Marie, Weinhold, Niels, Kimber, Scott, van Duin, Mark, Thorleifsson, Gudmar, Holroyd, Amy, Johnson, David C., Li, Ni, Orlando, Giulia, Law, Philip J., Ali, Mina, Chen, Bowang, Mitchell, Jonathan S., Gudbjartsson, Daniel F., Kuiper, Rowan, Stephens, Owen W., Bertsch, Uta, Broderick, Peter, Campo, Chiara, Bandapalli, Obul R, Einsele, Hermann, Gregory, Walter A., Gullberg, Urban, Hillengass, Jens, Hoffmann, Per, Jackson, Graham H., Jöckel, Karl-Heinz, Johnsson, Ellinor, Kristinsson, Sigurður Y., Mellqvist, Ulf-Henrik, Nahi, Hareth, Easton, Douglas, Pharoah, Paul, Dunning, Alison, Peto, Julian, Canzian, Federico, Swerdlow, Anthony, Eeles, Rosalind A., Kote-Jarai, Zsofia, Muir, Kenneth, Pashayan, Nora, The PRACTICAL consortium, Nickel, Jolanta, Nöthen, Markus M., Rafnar, Thorunn, Ross, Fiona M., da Silva Filho, Miguel Inacio, Thomsen, Hauke, Turesson, Ingemar, Vangsted, Annette, Andersen, Niels Frost, Waage, Anders, Walker, Brian A., Wihlborg, Anna-Karin, Broyl, Annemiek, Davies, Faith E., Thorsteinsdottir, Unnur, Langer, Christian, Hansson, Markus, Goldschmidt, Hartmut, Kaiser, Martin, Sonneveld, Pieter, Stefansson, Kari, Morgan, Gareth J., Hemminki, Kari, Nilsson, Björn, and Houlston, Richard S.

Published
2019
Full Text
View/download PDF

33. Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma

Author

Facon, Thierry, primary, Kumar, Shaji K, additional, Plesner, Torben, additional, Orlowski, Robert Z, additional, Moreau, Philippe, additional, Bahlis, Nizar, additional, Basu, Supratik, additional, Nahi, Hareth, additional, Hulin, Cyrille, additional, Quach, Hang, additional, Goldschmidt, Hartmut, additional, Perrot, Aurore, additional, Weisel, Katja, additional, Raje, Noopur, additional, Macro, Margaret, additional, Frenzel, Laurent, additional, Leleu, Xavier, additional, Wang, Jianping, additional, Rampelbergh, Rian Van, additional, Uhlar, Clarissa M, additional, Vermeulen, Jessica, additional, Duran, Joana, additional, Borgsten, Fredrik, additional, and Usmani, Saad Z, additional

Published
2023
Full Text
View/download PDF

34. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma

Author

Moreau, Philippe, primary, van de Donk, Niels WCJ, additional, Nahi, Hareth, additional, Oriol, Albert, additional, Nooka, Ajay K, additional, Martin, Thomas, additional, Rosinol, Laura, additional, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Mateos, Maria-Victoria, additional, Popat, Rakesh, additional, Martínez-López, Joaquín, additional, Sidana, Surbhi, additional, Delforge, Michel, additional, Pei, Lixia, additional, Trancucci, Danielle, additional, Olyslager, Yunsi, additional, Uhlar, Clarissa, additional, Stephenson, Tara, additional, Rampelbergh, Rian Van, additional, Banerjee, Arnob, additional, Kobos, Rachel, additional, and Usmani, Saad Z, additional

Published
2023
Full Text
View/download PDF

35. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

Author

Dimopoulos, Meletios A., primary, Oriol, Albert, additional, Nahi, Hareth, additional, San-Miguel, Jesus, additional, Bahlis, Nizar J., additional, Usmani, Saad Z., additional, Rabin, Neil, additional, Orlowski, Robert Z., additional, Suzuki, Kenshi, additional, Plesner, Torben, additional, Yoon, Sung-Soo, additional, Ben Yehuda, Dina, additional, Richardson, Paul G., additional, Goldschmidt, Hartmut, additional, Reece, Donna, additional, Ahmadi, Tahamtan, additional, Qin, Xiang, additional, Garvin Mayo, Wendy, additional, Gai, Xue, additional, Carey, Jodi, additional, Carson, Robin, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

36. Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Author

Janssen Research and Development, Nahi, Hareth, Usmani, Saad Z., Mateos, Maria Victoria, Donk, Niels W. C. J. van de, Oriol, Albert, Plesner, Torben, Bandyopadhyay, Nibedita, Hellemans, Peter, Tromp, Brenda, Nnane, Ivo, Zemlickis, Donna, Chari, Ajai, Moreau, Philippe, Janssen Research and Development, Nahi, Hareth, Usmani, Saad Z., Mateos, Maria Victoria, Donk, Niels W. C. J. van de, Oriol, Albert, Plesner, Torben, Bandyopadhyay, Nibedita, Hellemans, Peter, Tromp, Brenda, Nnane, Ivo, Zemlickis, Donna, Chari, Ajai, and Moreau, Philippe

Abstract

Daratumumab is approved as monotherapy and in combination regimens for the treatment of relapsed or refractory multiple myeloma (RRMM) or newly diagnosed multiple myeloma [Citation1,Citation2]. The PAVO study (ClinicalTrials.gov Identifier: NCT02519452) of daratumumab plus recombinant human hyaluronidase PH20 (rHuPH20; ENHANZE® drug delivery technology, Halozyme, Inc., San Diego, CA) in a mix-and-deliver formulation (part 1) or a pre-mixed subcutaneous formulation (DARA SC; part 2) demonstrated consistent safety, pharmacokinetics, and efficacy as the daratumumab intravenous (IV) formulation in patients with RRMM [Citation3–5].

Published
2023

37. Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma

Author

Nahi, Hareth, Afram, Gabriel, Uttervall, Katarina, Lockmer, Sandra, Tätting, Love, Gahrton, Gosta, Kashif, Muhammad, Alici, Evren, Stromberg, Olga, Klimkowska, Monika, Lund, Johan, Nahi, Hareth, Afram, Gabriel, Uttervall, Katarina, Lockmer, Sandra, Tätting, Love, Gahrton, Gosta, Kashif, Muhammad, Alici, Evren, Stromberg, Olga, Klimkowska, Monika, and Lund, Johan

Abstract

Background: The presence of minimal residual disease (MRD+) following autologous stem cell transplantation (ASCT) in multiple myeloma represents a poor prognostic factor for progression-free survival (PFS) and overall survival (OS).Methods: At our department, we recommend lenalidomide maintenance for patients who are MRD+ after ASCT, while MRD-negative (MRD-) patients, after information about the national guidelines, were not advised to follow this regimen.Results: Out of the total 228 patients, 175 received ASCT following first-line induction (MRD- 92 (53%), MRD+ 83 (47%), at 2 months post-ASCT), while 53 underwent ASCT after second-line treatment (MRD- 27 (51%), MRD+ 26 (49%), at the same time point). Comparatively, MRD- patients who did not receive maintenance demonstrated better OS than MRD+ patients who received upfront ASCT and maintenance treatment (96% vs. 86%, p = 0.030, at 3 years). However, nonsignificant difference was found in PFS (76% vs. 62%, at 3 years). Furthermore, second-line ASCT, MRD- non-maintained patients exhibited significantly better PFS than MRD+ (71% vs. 27%, p > 0.001, at 3 years). However, OS was better but nonsignificant (96% vs. 76%, at 3 years). Fluorescence in situ hybridization (FISH) analysis was performed on 141 out of the 228 patients. Of these, 85 (60%) patients were deemed standard risk (SR), and 56 (40%) were classified as high risk (HR). In the SR cohort, MRD- patients exhibited better PFS and OS than MRD+ patients (71% vs. 59% and 100% vs. 85%, respectively). In the HR cohort, the MRD- patients showed superior PFS but similar OS compared to MRD+ patients (66% vs. 42% and 81% vs. 80%, respectively).Conclusions: Our results indicate that being MRD- is a more crucial prognostic factor for the 3-year PFS and OS than the presence of high-risk cytogenetic markers or undergoing maintenance treatment. The latter appears insufficient, particularly for MRD+ patients following ASCT in the second-line setting, suggesting that th, Funding Agencies|We would like to extend our gratitude to all patients and their families who participated in this study. Their willingness to contribute has been crucial for the continuation of our research. We would also like to acknowledge the invaluable work of our col

Published
2023
Full Text
View/download PDF

40. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

Author

Giralt, Sergio, Garderet, Laurent, Durie, Brian, Cook, Gordon, Gahrton, Gosta, Bruno, Benedetto, Hari, Paremesweran, Lokhorst, Henk, McCarthy, Phillip, Krishnan, Amrita, Sonneveld, Pieter, Goldschmidt, Harmut, Jagannath, Sundar, Barlogie, Bart, Mateos, Maria, Gimsing, Peter, Sezer, Orhan, Mikhael, Joseph, Lu, Jin, Dimopoulos, Meletios, Mazumder, Amitabha, Palumbo, Antonio, Abonour, Rafat, Anderson, Kenneth, Attal, Michel, Blade, Joan, Bird, Jenny, Cavo, Michele, Comenzo, Raymond, de la Rubia, Javier, Einsele, Hermann, Garcia-Sanz, Ramon, Hillengass, Jens, Holstein, Sarah, Johnsen, Hans Erik, Joshua, Douglas, Koehne, Guenther, Kumar, Shaji, Kyle, Robert, Leleu, Xavier, Lonial, Sagar, Ludwig, Heinz, Nahi, Hareth, Nooka, Anil, Orlowski, Robert, Rajkumar, Vincent, Reiman, Anthony, Richardson, Paul, Riva, Eloisa, San Miguel, Jesus, Turreson, Ingemar, Usmani, Saad, Vesole, David, Bensinger, William, Qazilbash, Muzaffer, Efebera, Yvonne, Mohty, Mohamed, Gasparreto, Christina, Gajewski, James, LeMaistre, Charles F., Bredeson, Chris, Moreau, Phillipe, Pasquini, Marcelo, Kroeger, Nicolaus, and Stadtmauer, Edward

Published
2015
Full Text
View/download PDF

41. Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Author

Nahi, Hareth, primary, Usmani, Saad Z., additional, Mateos, Maria-Victoria, additional, van de Donk, Niels W. C. J., additional, Oriol, Albert, additional, Plesner, Torben, additional, Bandyopadhyay, Nibedita, additional, Hellemans, Peter, additional, Tromp, Brenda, additional, Nnane, Ivo, additional, Zemlickis, Donna, additional, Chari, Ajai, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

42. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

Author

Went, Molly, Sud, Amit, Försti, Asta, Halvarsson, Britt-Marie, Weinhold, Niels, Kimber, Scott, van Duin, Mark, Thorleifsson, Gudmar, Holroyd, Amy, Johnson, David C., Li, Ni, Orlando, Giulia, Law, Philip J., Ali, Mina, Chen, Bowang, Mitchell, Jonathan S., Gudbjartsson, Daniel F., Kuiper, Rowan, Stephens, Owen W., Bertsch, Uta, Broderick, Peter, Campo, Chiara, Bandapalli, Obul R, Einsele, Hermann, Gregory, Walter A., Gullberg, Urban, Hillengass, Jens, Hoffmann, Per, Jackson, Graham H., Jöckel, Karl-Heinz, Johnsson, Ellinor, Kristinsson, Sigurður Y., Mellqvist, Ulf-Henrik, Nahi, Hareth, Easton, Douglas, Pharoah, Paul, Dunning, Alison, Peto, Julian, Canzian, Federico, Swerdlow, Anthony, Eeles, Rosalind A., Kote-Jarai, ZSofia, Muir, Kenneth, Pashayan, Nora, Nickel, Jolanta, Nöthen, Markus M., Rafnar, Thorunn, Ross, Fiona M., da Silva Filho, Miguel Inacio, Thomsen, Hauke, Turesson, Ingemar, Vangsted, Annette, Andersen, Niels Frost, Waage, Anders, Walker, Brian A., Wihlborg, Anna-Karin, Broyl, Annemiek, Davies, Faith E., Thorsteinsdottir, Unnur, Langer, Christian, Hansson, Markus, Goldschmidt, Hartmut, Kaiser, Martin, Sonneveld, Pieter, Stefansson, Kari, Morgan, Gareth J., Hemminki, Kari, Nilsson, Björn, Houlston, Richard S., and The PRACTICAL consortium

Published
2018
Full Text
View/download PDF

44. Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial

Author

Jakobsen Falk, Ingrid, Lund, Johan, Gréen, Henrik, Gruber, Astrid, Alici, Evren, Lauri, Birgitta, Blimark, Cecilie, Mellqvist, Ulf-Henrik, Swedin, Agneta, Forsberg, Karin, Carlsson, Conny, Hardling, Mats, Ahlberg, Lucia, Lotfi, Kourosh, and Nahi, Hareth

Published
2017
Full Text
View/download PDF

46. Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Author

Perrot, Aurore, primary, Facon, Thierry, additional, Plesner, Torben, additional, Usmani, Saad, additional, Kumar, Shaji K, additional, Bahlis, Nizar Jacques, additional, Hulin, Cyrille, additional, Orlowski, Robert Z., additional, Nahi, Hareth, additional, Mollee, Peter, additional, Ramasamy, Karthik, additional, Roussel, Murielle, additional, Jaccard, Arnaud, additional, Delforge, Michel, additional, Karlin, Lionel, additional, Arnulf, Bertrand, additional, Chari, Ajai, additional, Pei, Huiling, additional, Gupta, Niodita, additional, Kaila, Shuchita, additional, Matt, Kathryn, additional, Gries, Katharine S., additional, Carson, Robin, additional, Borgsten, Fredrik, additional, and Weisel, Katja, additional

Published
2022
Full Text
View/download PDF

47. Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Author

Facon, Thierry, primary, Kumar, Shaji K, additional, Weisel, Katja, additional, Usmani, Saad, additional, Moreau, Philippe, additional, Plesner, Torben, additional, Orlowski, Robert Z., additional, Bahlis, Nizar Jacques, additional, Basu, Supratik, additional, Nahi, Hareth, additional, Hulin, Cyrille, additional, Quach, Hang, additional, O'Dwyer, Michael, additional, Perrot, Aurore, additional, Venner, Christopher P., additional, Raje, Noopur, additional, Tiab, Mourad, additional, Macro, Margaret, additional, Frenzel, Laurent, additional, Leleu, Xavier, additional, Pei, Huiling, additional, Carson, Robin, additional, Borgsten, Fredrik, additional, and Goldschmidt, Hartmut, additional

Published
2022
Full Text
View/download PDF

48. Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Author

Moreau, Philippe, primary, Facon, Thierry, additional, Usmani, Saad, additional, Bahlis, Nizar Jacques, additional, Raje, Noopur, additional, Plesner, Torben, additional, Orlowski, Robert Z., additional, Basu, Supratik, additional, Nahi, Hareth, additional, Hulin, Cyrille, additional, Quach, Hang, additional, Goldschmidt, Hartmut, additional, O'Dwyer, Michael, additional, Perrot, Aurore, additional, Venner, Christopher P., additional, Weisel, Katja, additional, Tiab, Mourad, additional, Macro, Margaret, additional, Frenzel, Laurent, additional, Leleu, Xavier, additional, Pei, Huiling, additional, Krevvata, Maria, additional, Carson, Robin, additional, Borgsten, Fredrik, additional, and Kumar, Shaji K, additional

Published
2022
Full Text
View/download PDF

49. Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Author

Kumar, Shaji K, primary, Moreau, Philippe, additional, Bahlis, Nizar Jacques, additional, Facon, Thierry, additional, Plesner, Torben, additional, Orlowski, Robert Z., additional, Basu, Supratik, additional, Nahi, Hareth, additional, Hulin, Cyrille, additional, Quach, Hang, additional, Goldschmidt, Hartmut, additional, O'Dwyer, Michael, additional, Perrot, Aurore, additional, Venner, Christopher P., additional, Weisel, Katja, additional, Raje, Noopur, additional, Tiab, Mourad, additional, Macro, Margaret, additional, Frenzel, Laurent, additional, Leleu, Xavier, additional, Pei, Huiling, additional, Krevvata, Maria, additional, Carson, Robin, additional, Borgsten, Fredrik, additional, and Usmani, Saad, additional

Published
2022
Full Text
View/download PDF

50. Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy

Author

Susek, Katharina H., primary, Schwietzer, Ysabel A., additional, Karvouni, Maria, additional, Gilljam, Mari, additional, Keszei, Marton, additional, Hussain, Alamdar, additional, Lund, Johan, additional, Kashif, Muhammad, additional, Lundqvist, Andreas, additional, Ljunggren, Hans-Gustaf, additional, Nahi, Hareth, additional, Wagner, Arnika K., additional, and Alici, Evren, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results